Download FREE Report Sample
Download Free sampleTumour-induced osteomalacia or oncogenic osteomalacia is a rare paraneoplastic syndrome of bone which consist of osteomalacia or rickets induced by phosphaturic mesenchymal tumour (PMT). Tumour-induced osteomalacia diagnosed with an elevated level of blood fibroblast growth factor 23 (FGF23), phosphate and vitamin D-regulating hormone.
Tumour-Induced Osteomalacia Market contains market size and forecasts of Tumour-Induced Osteomalacia in Global, including the following market information:
Global Tumour-Induced Osteomalacia Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Tumour-Induced Osteomalacia market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Tumour-Induced Osteomalacia include Kyowa Kirin, Taizhou Hisound Pharmaceutical, Zhejiang Garden Biochemical High-tech, Kingdomway Nutrition, Amgen, Forgo Pharmaceuticals, Abbott, Solvay and GE Healthcare and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Tumour-Induced Osteomalacia companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tumour-Induced Osteomalacia Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Tumour-Induced Osteomalacia Market Segment Percentages, by Type, 2021 (%)
Drugs
Supplements
Surgery
Others
Global Tumour-Induced Osteomalacia Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Tumour-Induced Osteomalacia Market Segment Percentages, by Application, 2021 (%)
Laboratories
Bone Scan
Differential Diagnosis
Others
Global Tumour-Induced Osteomalacia Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Tumour-Induced Osteomalacia Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tumour-Induced Osteomalacia revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Tumour-Induced Osteomalacia revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Kyowa Kirin
Taizhou Hisound Pharmaceutical
Zhejiang Garden Biochemical High-tech
Kingdomway Nutrition
Amgen
Forgo Pharmaceuticals
Abbott
Solvay
GE Healthcare
Siemens
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
